Skip to content

By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation

By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03880721
Enrollment
200
Registered
2019-03-19
Start date
2019-01-01
Completion date
2021-04-30
Last updated
2019-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

radiomics, prognosis

Brief summary

Developing a radiomics model to predict the prognosis of patients with hepatocellular carcinoma after microwave ablation to provide advice for their treatment.

Interventions

PROCEDUREMicrowave abaltion

Use microwave ablation to treat hepatocellular carcinoma

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients with primary hepatocellular carcinoma in the department of interventional ultrasound, PLA general hospital, who accept MWA therapy for HCC Inclusion criteria: 1. Primary hepatocellular 2. No other treatments ware performed before microwave ablation 3. Patient has been clinically diagnosed with HCC definitely, and have a definite operational indication 4. No extrahepatic manifestations and no evidence of vessel invasion and bile duct thrombi

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
AUC valuethrough study completion, an average of 2 yearUtilizing area under curve to judge the accurency
Sensitivitythrough study completion, an average of 2 yeardiagnosis sensitivity of intelligent ultrasound analysis
Specificitythrough study completion, an average of 2 yeardiagnosis specificity of intelligent ultrasound analysis

Countries

China

Contacts

Primary ContactJie Yu, Dr
yu-jie301@hotmail.com8610-66939530
Backup ContactPing Liang, Dr
liangping301@hotmail.com8610-66939530

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026